The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group have agreed to supply Avifavir, the world’s first registered favipiravir-based drug against coronavirus and Russia’s first drug approved for the treatment of COVID-19, to 17 countries.

Avifavir and other favipiravir-based drugs produced in Russia, as well as Remdesivir developed in the US are currently the leading drugs against COVID-19registered globally.

Avifavir will be delivered to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia,South Africa, UAE and Uruguay.

The drug has already been delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.